Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD5-HP2H6 | Human | PE-Labeled Human CD5 Protein, His Tag (Site-specific conjugation) | ![]() |
![]() ![]() |
|
CD5-H5253 | Human | Human CD5 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD5-H82F3 | Human | Biotinylated Human CD5 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
CD5-H82E5 | Human | Biotinylated Human CD5 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
CD5-H52H2 | Human | FITC-Labeled Human CD5 Protein, His Tag | ![]() |
![]() ![]() |
|
CD5-H52H5 | Human | Human CD5 Protein, His Tag | ![]() |
![]() ![]() |
5e5 of anti-CD5 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD5, His Tag (Cat. No. CD5-HP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
The purity of Biotinylated Human CD5, Fc,Avitag (Cat. No. CD5-H82F3) is more than 90% and the molecular weight of this protein is around 155-175 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD5 CAR T Cell Therapy (Beijing Boren Hospital) | Phase 1 Clinical | Beijing Boren Hospital | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CT-125A | CT-125A; RD-125 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, T-Cell, Peripheral; Lymphoma, Mantle-Cell; Plasmablastic Lymphoma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.